updat compani view usd hg
coverag rate report
today pass along updat view healthcar name
coverag conjunct broader group usd high grade coverag
rate report
page follow present updat summari comment
cover compani detail individu rate view want
call attent item attach commentari first
downgrad uw given view market becom
complac settlement discuss given see
weakest posit distributor head possibl global settlement
also move neutral rate rate follow period
restrict though note posit bia rel devic name see
valuat fairli attract rel peer space addit
termin coverag celg follow close transact
given substanti major old celg debt within
legal entiti structur legaci debt
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
tabl healthcar servic recommend commentari
ci remain one top pick continu view esrx merger
posit think de-lever meaning de-risk stori see
recent sale disabl busi reduc event risk near
term debt reduct continu primari focu evidenc
compani use cash flow compani repaid
year compani ow explicit commentari plan
repay debt year continu see
reason ci achiev de-lever goal upper debt-to-
cap end debt-to-cap improv
compani continu de-lever progress sale
group benefit busi provid cushion plan despit
share repurchas compani may see catalyst
compani includ abil recov break fee relat
compani fail merger risk rate includ environment
polit chang leav pbm manag organ
disadvantag aggress balanc sheet manag expect
advers court rule litig
maintain posit view oper fair
compani continu show conserv tone relat balanc sheet
capit manag primari support recommend
someth expect continu ith sw irl uncertainti
around healthcar market lab go radar
extent see major chang horizon spread
year bond slightli behind lh see valu bond
rel lh ell compani ithin healthcar risk
rate includ oper challeng sharehold pressur
aggress ith balanc sheet sizabl debt-financ
aetna legal entiti holli ow ned non-guarante subsidiari
holdco hich structur senior parent debt
perspect aet insurance-gener cash flow believ aet
trade persist insid due structur senior
low er dollar price latest issu bond maintain separ rate
aet compar may decid absorb rate
time depend disclosur made compani risk rate
dow nside includ oper setback lack focu
aet ticker caus investor prefer manag care name
 hile risk upsid includ liabil manag reduc debt
subsidiari level
despit result recent quarter show ing busi stabil
remain cautiou current valuat given continu overhang
on-going opioid litig like mani peer believ event risk merit
monitor advanc near-term litig addit drug price pressur
increas scrutini pharmaceut suppli chain also leav
compani suscept chang environ time opioid
posit sentiment built surround near-term settlement led
tighten past sever month even materi uncertainti still
remain go forw ard believ uncertainti surround name
 ill hold valuat back time head trial ny
 hich set begin march report
addit seven state one us territori join back global
settlement offer recent eek recent report suggest nearli
tw dozen state citi counti still sign
say term still good enough dollar amount low time
frame payment long posit compani low er leverag
peer though see absorb ithin current valuat risk
rate upsid includ global resolut opioid litig
near-term level commensur ith compani balanc sheet
spread number year combin ith busi stabil hile
risk dow nside includ advers develop opioid reflect
long-term uncertainti risk materi higher payout
tabl healthcar servic recommend commentari cont
laboratori corp
see reason level market peer
manag space favor view ed commit
credit profil despit oper setback face earli ith
commit manifest compani june investor day
comment ell decis includ leverag target part
execut compens formula still expect compani ill report
fairli stabl earn go forw ard believ commit improv
balanc sheet think forw ard guidanc achiev see spread
price fair amount improv compani credit profil
given ed like see de-risk stori return
posit stanc compani project slightli low er cfo
vs expect cash avail debt
repay year hich note modestli low er
expect view posit compani retier
remain track achiev target leverag ratio low
someth continu view achiev ell hand
think bond spread price risk potenti opioid
develop hich hile believ exposur low er other
potenti leav compani subject headlin risk also see addit
headlin risk disrupt regulatori oper constant
sourc nois segment hich compet upsid
dow nside risk offset view
balanc view credit
hold neutral rate amidst chang environ
compani oper result strong
 ith compani show ing stabil medic loss ratio
futur sector uncertain manag express desir
maintain financi strateg flexibl continu evalu strateg
acquisit build capabl particularli primari care compani
comment ill continu deploy capit effici manner
 ith target debt-to-cap ratio order maintain invest
grade credit rate though note abil move target
strateg result despit strong oper perform
strong posit medicar advantag see event risk higher
compar peer go forw ard key item monitor risk
rate upsid includ sustain posit oper perform
conjunct ith conserv balanc sheet manag market
revisit possibl full acquisit higher-r peer hile risk
dow nside includ pursuit larg debt-financ renew ed
uncertaini regard move throughout democrat
posit lab gener prefer lh given current
valuat ith lh slightli insid neutral rate driven
fact much posit name de-lever post covanc get
high end leverag target envigo financ conserv
 ell fli radar midst recent servic subsector
uncertainti price point hile oper trend
good enough credit recent see big
next month compani plan much prospect debt
reduct believ event risk ill persist part stori
time risk dow nside includ aggress ith compani
say ould continu look attract tuck-in opportun given
balanc sheet strength favor debt matur schedul ell
sector disrupt leav independ lab disadvantag risk
upsid includ conserv balanc sheet manag expect
strong oper perform
tabl healthcar servic recommend commentari cont
continu face concern role opioid crisi settl
 ith tw ohio counti octob engag discuss
broader settlement similar distributor see market
much optim someth believ ill take time resolv pass
uncertainti look forw ard oper appear
stabil expect ill stay import part healthcar
suppli chain see uncertainti busi risk limit spread
out-performance time despit on-going litig
continu open balanc valuat expect
altern return capit risk rate includ posit
turnaround environ financi conservat expect
near-term resolut potenti opioid liabil hile neg risk includ
acceler industri competit continu eak price
environ healthcar reform advers affect distributor
potenti larg opioid settlement market expect
 ould neg affect balanc sheet health
see best posit compani manag space
 view compani diversif unregul cash flow strong
credit posit firm diversifi ithin medic benefit
busi it strong result optum servic
offer addit hile compani debt-to-capit end year
unchang y/i strong cash flow capit grow th
enabl delev faster peer past note higher
leverag metric less issu rel peer given
larg servic busi comfort ith exposur
compani overal diversifi busi model appear insul
headlin sw irl around greater manag space current
valuat ell insid peer hold us back posit
view nside risk rate includ slow ed pace de-lever
 ell oper setback core insur servic busi
nois given on-going industri debat pharma suppli chain
futur privat health insur convers risk upsid includ
strong result across busi line addit de-lever
tabl healthcar servic recommend commentari cont
dow ngrade recommend neutral
underw eight given current valuat believ adequ
reflect opioid litig risk view market becom
complac relat risk addit neg develop surround
opioid expect litig ill continu primari factor drive
spread expect settlement discuss ill overhang
prolong period time expect new flow pick approach
near term trial ny ca trial recent result improv
oper especi pharma segment see less
import credit compar equiti balanc see
 eakest posit distributor head possibl global settlement
 see risk uncertan surround settlement
adequ price current level recent report suggest
number state citi counti su distributor
continu reject origin offer year instead request
larger sum shorter period time see neg
given broad percept distributor pay even
lack cushion current rate current see richest
part capit structur posit note compani
commit repay least debt note
expect futur capit deploy ill disciplin risk
rate includ potenti turnaround price trend could
substanti boost profit balanc sheet conservat near-term
favor resolut opioid litig
even risk surround seem diminish time
 maintain uw rate continu see better
opportun peer remain concern potenti event risk
overhang uncertain manag environ hich expect
persist near-term rate also inform elev leverag
debt-to-capit end year hich compani note
consist ith target rang open potenti risk
outstand ci litig remain focus tuck-in
recent said take anyth tabl point time ill
react market condit accordingli hile expect ill
eventu pay break fee ci believ
upsid potenti court rule favor demand payment
continu believ spread ill under-perform peer risk rate
includ potenti shift tow ard conserv financi polici
improv oper perform ell posit develop
relat risk
tabl pharma/med devic recommend commentari
co
strong oper pipelin profil follow ing close
celg transact off-set elev debt level continu view
credit posit see compani de-lever plan achiev
due compani strong cash flow gener commit
reduc debt especi given initi debt level combin compani
significantli reduc follow ing dispos otezla ith
compani say proce sale ill priorit reduc near-
term debt avoid excess initi leverag compani recent
increas share repurchas author see program
line ith size de-lever commit expect
achiev gross leverag end believ continu
de-lever de-risk stori advanc revlimid lose patent
protect medium term believ compress
peer make de-lever progress opdivo maintain good posit pd-
advers develop revlimid patent situat
time expect compani ill conserv peer
risk rate includ chang manag disposit tow ard
financi polici debt paydow pace slow er anticip larger
scale pipelin failur advers revlimid develop
recent spread under-perform left us littl posit bias
credit neutral view remain essenc fair spread level
off-set uncertain outlook open focu continu futur
 percept market higher event risk like hold
spread back time still comfort ith credit note
compani consist paid dow debt sinc tax reform gave
access global cash flow kept share repurchas dividend
line ith free cash flow compani said expect repurchas
share follow ing acquisit otezla
stake beigen cash balanc declin
end note compani issu note
februari refin upcom matur see
tw transact rel low risk credit perspect follow ing
deal note capit alloc prioriti remain intact
state ill continu invest grow th busi
intern extern note remain commit maintain
optim capit structur retain ig rate time ill
continu atch high proport matur drug ithin portfolio
effort biosimilar front risk rate includ potenti
substanti debt-fund convers balanc sheet conservat
could lead de-lever slow er pace issuanc
surpris announc regard extensive-than-expect
issu alari pump busi hich requir new clearanc
fda clear neg credit view develop
may potenti delay previou expect market expect
upgrad back ig near term believ agenc
 ill need clariti surround impact fda request
posit side gross leverag end recent quarter
unchang q/q compani calcul basi initi leverag
bcr transact rang hich consist ith plan
delev decemb talk float
mid-to-low time capit alloc compani
said look cash flow ill look expand
specif tuck-in said interest anoth
larg deal histor expect compani ould activ
 held recommend back somew hat risk rate
dow nside includ busi setback could lead oper pressur
includ neg develop relat alari pump
busi ell exposur market beta sentiment risk
upsid includ potenti compani pursu divestitur alter
financ plan accordingli improv rate sooner expect
faster anticip resolut ith fda
tabl pharma/med devic recommend commentari cont
move neutral rate rate follow ing period
restrict posit bias tow ard credit rel devic
name overal see valuat fairli attract rel peer
believ posit option time credit given
compani statement ant delev year
debt repay target bbb credit rate time
addit compani show oper result held
rel ell credit despit oper hiccup near term
rate held back somew hat averag exposur china
uncertainti relat impact china
countri despit concern ould use eak increas
posit risk rate upsid includ resolut
concern return normal surgic procedur ell compani
exhibit conservat balanc sheet perspect execut
de-lever look rate upgrad time risk
dow nside includ global challeng due effect larg
view evolv cautiou recent
maintain recommend neutral given recent under-perform
overal spread level rel elev debt level post
fund loxo deal earli upcom loe sever
major product addit base recent commentari expect higher
 activ compar peer compani comment ould target
one per quarter deal rang expect fairli high
level sharehold return risk upsid rate includ
acceler repay debt hile risk dow nside includ less
conserv financi polici addit opportun compani
 ork off-set product loe
follow ing recent commentari comfort ith manag
chang believ market price much risk larg
compani commit transpar portfolio decis
make reiter overal capit alloc prioriti remain
unchang ith approach extern partnership driven
scienc share repurchas remain modest larg
consist ith statu quo someth view continu
support credit possibl develop remdisivir potenti treatment
import could posit compani
 hole though see benefit accru creditor see
catalyst equiti also notabl compani continu pay
dow debt repay time frame issu
market sinc see larg cash balanc posit
insul factor event risk expect market give
credit past risk upsid includ
conserv balanc sheet manag expect compani
continu hold larg amount cash balanc sheet risk
dow nside includ chang financi polici includ possibl sharehold
pressur aggress ith balanc sheet potenti
larger acquisit lead rate pressur ell neg
develop relat truvada patent law suit ith govern
tabl pharma/med devic recommend commentari cont
recent announc plan spin omen health legaci brand
biosimilar busi compani expect receiv
special tax-fre dividend part process ith compani
comment plan alloc capit tow ard busi develop
share repurchas debt repay ad expect
maintain solid financi credit profil note dow ngrade
compani aa- like dow ngrade close
keytruda continu success compani stabl oper
therapeut categori see valuat tight end
compani peer set fair hen consid posit neg
compar mani peer manag continu de-emphas
large-scal focus deal believ value-ad
 ith minimum disrupt on-going scientif effort compani also note
see chang approach busi develop time
strategi standpoint result spin light see risk
larg debt-financ acquisit low compar other space
risk upsid includ addit posit pipelin result along ith
limit deal make strengthen compani alreadi high-qual balanc
sheet flight qualiti event market sell-off hile risk
dow nside includ larg debt-financ signific financi polici
look forw ard combin ith upjohn unit continu
feel comfort ith credit given stand-alone de-lever progress
continu commit ig plan viatri credit profil
addtion view chang manag much team
includ recent announc cfo remov netherland
sticht structur posit ever feel take
posit stanc credit market need clariti earn
trajectori chines market includ potenti impact
compani oper get debt issuanc
clariti come item believ time spread
compress peer risk upsid includ myl-upjohn deal
close ith combin compani manag balanc sheet
conserv trend chines market stabil hile risk
dow nside includ deal fall apart unanticip neg chines market
dynam ell neg develop relat on-going price
valuat remain ide continu see long-term uncertainti
 note recent approv gproair posit could
catalyst sale busi compani provid updat
progress sinc hen state ould need evalu
time separ due uncertainti market gener
pharmaceut industri believ environ becom
anymor favor sinc also see busi oper challeng
persist recent announc ranir transact lessen flexibl
potenti addit need time variou on-going tax issu
potenti signific hen compar size compani
said even though view rate safe
agenc incorpor tax uncertainti rate
compani reiter commit debt paydow invest
grade rate say ant leverag eventu mani
neg uncertainti stori like keep spread ide
level near term see show stori ill
need prove bond outperform risk rate
dow nside includ potenti eak oper result abandon rx
separ eaken compani ig commit aggress
 risk upsid includ potenti better oper result
execut sale rx busi ell quick resolut ith
irish tax author ir
tabl pharma/med devic recommend commentari cont
show steadi oper perform fair balanc sheet
off-set current valuat believ appropri reflect
dynam current sit tight end fair valu also expect
rate ill stay leverag ill remain zone
guid manag view firm oper posit thank
lead posit credit-friendli anim health industri consist
oper result last year also note recent
transit ceo begin ith kristin peck former evp
presid us oper take risk dow nside includ
potenti firm significantli increas leverag fund major
transact though note abil pursu large-scal deal
sector limit anti-trust concern market share manag
indic desir pursu risk upsid includ continu
oper strength conserv balanc sheet manag
compani state past plan lever balanc sheet
time net leverag someth ould requir signific
increment debt current level ever signific time pass
 ithout dramat action net leverag current sit slightli
posit expect remain risk
someth expect compani ill pursu time view
like present persist risk caus spread trade ide
investor feel resolut reach addit compani
inform us sec intern investig intra-compani
transact undertaken purpos gener fx gain loss
date back least note recent eek compani
releas preliminari revis seem overli materi credit
perspect though plan releas full financi end
someth ould still like see order take construct
stanc risk rate includ mute pace balanc
sheet re-lev continu prefer market devic name
healthcar sector
uw view come tight valuat compar peer
persist threat lack product diversif ell
compani limit debt footprint capac leverag increas
relat aducanumab materi uncertanti remain view includ
 hether fda ill ultim approv submiss ould
logic think larg ould tabl ait fda
decis aducanumab comment strong interest
build pipelin remain engag busi develop
opportun someth note independ event
oper result remain fair leverag remain low also
concern compani relianc ms drug hile
compani recent patent challeng relat tecfidera note ill
face tw addit challeng later year futur event risk
overal regulatori environ compani go forw ard risk
rate includ near-term approv aducanumab conserv
balanc sheet manag expect
tabl pharma/med devic recommend commentari cont
 morgan mid g-spread eod cd mid spread
view one strongest compani sector ith
substanti diversif across consum medic devic pharma
market ever compani trade tight level present
limit upsid view addit talc litig repres
unpredict risk ill like take extend period time play
compani also involv signific opioid litig hich like
consistenli eigh sentiment focus compani
remain open acquisit comment remain activ across
pharma consum medic devic busi ad
 ould expect on-going cadenc activ
differ area addit place compani
aaa rate review dow ngrade believ litig
overhang could pressur rate time long term expect
compani ill face increas call split lever time
 expect ill gain much traction risk rate includ potenti
firm undertak signific debt reduct degre
resolut litig near term
follow ing close transact ith termin coverag
celg given substanti major old celg debt ithin
legal entiti structur legaci debt per
term exchang
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect research analyst person view subject secur issuer
part research analyst compens directli indirectli relat specif recommend
view express research analyst report korea-bas research analyst list front cover applic
also certifi per kofia requir analysi made good faith view reflect opinion
without undu influenc intervent
author name within report research analyst unless otherwis specifi europ sector specialist may shown
report contact author report part research depart
